908 Devices Q2 Revenue Jumps 23%, Raises Low End of 2026 Outlook
MASS sits 73% above its 52-week low of $5.025.
Summary
908 Devices posted Q2 revenue of $16.1M, up 23% year-over-year, driven by VipIR device sales and the addition of NIRLab. Adjusted EBITDA loss narrowed by more than half to $1.9M, showing improving operating leverage. The company raised the low end of its full-year 2026 revenue guidance to $68M-$70M, implying 21-25% growth. A strong balance sheet with $101.5M in cash and no debt provides ample runway. A post-quarter $6M ProtectIR order from an Asia-Pacific corrections agency adds visibility to the second half. This follows a recent 8-K disclosing a 3.2M share earnout issuance for the RedWave acquisition, but the strong cash position and narrowing losses suggest the dilution is being absorbed. The raised guidance and order momentum indicate accelerating commercial traction, particularly with U.S. state and local agencies.
At the time of this announcement, MASS was trading at $8.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $361M. The 52-week trading range was $5.03 to $9.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.